The use of PAD inhibitor BB-Cl-amidine has been assessed for PAD2 and PAD4 expression and shown to reduce viability and tumourigenicity of feline and canine mammary cancer lines by affecting ER stress, and furthermore tested in xenograft models [34]. Here, PADI2 is linked to breast cancer.